Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Biosimilars (2)
70 Articles Available
2
3
Can't find what you're looking for? Try our
advanced search
.
Biosimilar
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
PR-M01-19-NI-002
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on New Actions Advancing the Agency's Biosimilars Policy Framework
PR-M12-18-NI-049
Biosimilars
Pfizer’s Rituximab Biosimilar Achieves Positive Study Results
PAO-M12-18-NI-001
FDA Approval
FDA Approves First Biosimilar for Treatment of Adult Patients with Non-Hodgkin's Lymphoma
PR-M12-18-NI-004
Investment
US Tax Savings Help AbbVie
PAO-M11-18-NI-012
Biosimilars
Herceptin Biosimilar Gets Positive Opinion in Europe
PAO-M10-18-NI-024
FDA
Another Biosimilar Gets Nod from Independent FDA Panel
PAO-M10-18-NI-018
Biosimilars
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
PR-M10-18-NI-071
Biosimilars
Innovent Receives IND Approval to Initiate Clinical Trials in China with Sintilimab in Combination with its Biosimilar to Bevacizumab
PR-M10-18-NI-056
Biosimilars
U.S. Department of Veterans Affairs Signs Contract with Merck for its Remicade Biosimilar
PAO-M10-18-NI-010
Biosimilar
Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
PR-M09-18-NI-087
Biosimilar
Legislation Introduced to Require Reporting of Biosimilar Agreements
PAO-M08-18-NI-020
Biosimilar
FDA Issues New Biosimilar Action Plan
PR-M07-18-NI-074
Biosimilars
Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
PR-M06-18-NI-100
Biosimilars
Another mAb Biosimilar on the Horizon in Europe
PAO-M06-18-NI-006
FDA Approval
Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA
PR-M05-18-NI-071
Biosimilars
GlobalData Predicts Strong Sales for Humira Biosimilars in Europe
PAO-M05-18-NI-006
Oncology
MSD Launches Herceptin Biosimilar in UK
PAO-M03-18-NI-015
Biosimilar
Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
PR-M03-18-NI-017
Approval
Celltrion Receives EU Approval for Trastuzumab Biosimilar
PR-M02-18-NI-71
Biosimilars
Novartis Makes More Biosimilar Moves
PAO-M01-18-NI-047
Biosimilars
Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®
PR-M01-18-NI-092
Biosimilars
Sandoz - Biocon Deal One More Sign That U.S. Biosimilars Have Arrived
PR-M01-18-NI-086
Biosimilar
European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
PR-M01-18-NI-077
«
2
3
»
.svg)
